Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > So, about those 4 drugs CXR bought last quarter...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by tagon Aug 11, 2016 6:28pm
86 Views
Post# 25133257

RE:RE:So, about those 4 drugs CXR bought last quarter...

RE:RE:So, about those 4 drugs CXR bought last quarter...
LatticelnExile wrote:
select1011 wrote: ....when at least one good analyst asks for details about this acquisition tomo, what the drugs are, and what the contribution to Q2 revs are of these drugs. are all the longs on this board ok to accept an answer that might be something like, 'cant tell you because of competitive reasons'? That would be a classic WTF moment.

Select, I don't think Meihm is a "good analyst."  But he covered Biovail at the same time the SEC laid accounting fraud charges and fined them when the shares price pummeled on the investigation.  Also worthy of mention, Biovail's critics that got $10 Million in a settlement from Biovail for malicious prosecution....   So my eyes on him.  If anyone is going to do a secondary, it will be RBC IMO as they have been the most bullshitiest... errr... i mean... bullish...  analyst coverage frontrunning the 6 year non-investment grade paper.


Marc, you in Toronto?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities